Physician profile
Matthew Nersesian
NPI 1447575105
$3,133.49
in general payments reported to CMS, 2019-2025
23 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $436 · 2024: $1,506 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $498.42 | 2023-2025 | Azstarys, Azstarys |
| Ironshore Pharmaceuticals INC. | $468.13 | 2023-2024 | Jornay Pm |
| Pfizer INC. | $244.46 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $243.00 | 2023-2025 | Qelbree, Qelbree |
| Neurelis, INC. | $228.62 | 2023-2025 | Valtoco |
| Tris Pharma INC | $185.86 | 2023-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $180.07 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $175.45 | 2023-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Seqirus USA INC | $160.76 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $127.32 | 2024-2025 | |
| Glaxosmithkline, LLC. | $113.57 | 2023-2025 | Bexsero, Rotarix, Pediarix |
| Cranial Technologies, INC | $76.03 | 2023-2025 | Doc Band |
| Verrica Pharmaceuticals INC. | $59.43 | 2024-2025 | Ycanth |
| Neos Therapeutics, LP | $59.16 | 2024-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Ultragenyx Pharmaceutical INC. | $56.51 | 2023-2024 | Crysvita, Crysvita |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $50.77 | 2023-2024 | Auvi-Q |
| Vertical Pharmaceuticals, LLC | $48.51 | 2025 | Relexxii |
| Modernatx, INC. | $43.19 | 2023-2025 | Moderna Covid-19 Vaccine |
| Ars Pharmaceuticals Operations, INC. | $28.08 | 2025 | Neffy |
| Neuronetics, INC. | $25.07 | 2025 | Neurostar Tms Therapy System |
| Sobi, INC | $23.66 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.72 | 2024 | Koselugo |
| Sanofi Pasteur INC. | $16.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nersesian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.